MedPath

New Beta Innovation Limited

🇭🇰Hong Kong, China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (100.0%)

YQ23 Study in Patients With Critical Limb Ischaemia

Phase 1
Terminated
Conditions
Critical Limb Ischemia
First Posted Date
2021-03-10
Last Posted Date
2023-12-08
Lead Sponsor
New Beta Innovation Limited
Target Recruit Count
5
Registration Number
NCT04792008
Locations
🇭🇰

Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong

🇭🇰

Queen Mary Hospital, Hong Kong, Hong Kong

A Safety Study of YQ23 in Advanced Solid Tumors Patients

Phase 1
Terminated
Conditions
Advanced Solid Tumor
First Posted Date
2020-08-14
Last Posted Date
2023-12-08
Lead Sponsor
New Beta Innovation Limited
Target Recruit Count
3
Registration Number
NCT04513067
Locations
🇭🇰

The University of Hong Kong Phase I Clinical Trials Centre, Hong Kong, Hong Kong

First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23

Phase 1
Completed
Conditions
Healthy Volunteers
First Posted Date
2019-01-14
Last Posted Date
2021-03-03
Lead Sponsor
New Beta Innovation Limited
Target Recruit Count
58
Registration Number
NCT03802292
Locations
🇬🇧

Covance CRU Limited, Leeds, United Kingdom

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.